Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA as Adjuvant to Phototherapy in Neonatal Indirect Hyperbilirubinemia
NCT07110987Recruiting
- Sponsor
- Tishreen University Hospital
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of ursodeoxycholic acid in neonatal hyperbilirubinemia (2 arms), sponsored by Tishreen University Hospital. Primary endpoints: Reduction of total serum bilirubin to below phototherapy threshold, Time to bilirubin reduction below treatment threshold and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
neonatal hyperbilirubinemia
Beyond the preview
Go deeper on NCT07110987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110987.